Related Experiment Videos
[Disseminated mucormycosis in AIDS]
C Lagorce Pagès1, A Fabre, F Bruneel
1Service d'Anatomie et de Cytologie Pathologiques, Hôpital Bichat-Claude Bernard, Paris.
Annales De Pathologie
|October 4, 2000
Summary
Mucormycosis is a rare, fatal fungal infection primarily affecting immunocompromised individuals. This case highlights a fatal disseminated mucormycosis in an 18-year-old HIV+ patient, emphasizing the need for rapid diagnosis.
Area of Science:
- Mycology
- Infectious Diseases
- Immunocompromised Host Research
Background:
- Mucormycosis is a rare, opportunistic fungal infection with high mortality.
- It predominantly affects immunocompromised individuals, but is infrequently reported in Human Immunodeficiency Virus (HIV)-positive patients.
- Disseminated mucormycosis presents a significant diagnostic and therapeutic challenge.
Observation:
- An 18-year-old Human Immunodeficiency Virus (HIV)-positive male from Zaire presented with rapidly progressing disseminated mucormycosis.
- Fungal elements, identified as Rhizopus orizae, were observed with pronounced vascular tropism across multiple organs, including pulmonary, cardiac, renal, hepatic, splenic, and gastric systems.
- The extensive organ involvement and rapid progression underscore the aggressive nature of the infection in this patient.
Findings:
- The case demonstrates a rare occurrence of disseminated mucormycosis in an acquired immunodeficiency syndrome (AIDS) patient.
- Rhizopus orizae was identified as the causative agent through fungal cultures.
- Histopathological examination revealed extensive fungal invasion with a specific affinity for blood vessels across various organs.
Implications:
- Early microscopic diagnosis of mucormycosis, particularly in its localized stage, is crucial for improving patient outcomes.
- This case underscores the importance of considering mucormycosis in the differential diagnosis of opportunistic infections in HIV-positive individuals.
- Further research into risk factors and early detection strategies for mucormycosis in immunocompromised populations is warranted.